Imiquimod in the treatment of eyelid basal cell carcinoma
Article first published online: 22 MAR 2007
© 2007 The Authors
Acta Ophthalmologica Scandinavica
Volume 85, Issue 5, pages 566–568, August 2007
How to Cite
Leppälä, J., Kaarniranta, K., Uusitalo, H. and Kontkanen, M. (2007), Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmologica Scandinavica, 85: 566–568. doi: 10.1111/j.1600-0420.2007.00896.x
- Issue published online: 25 JUL 2007
- Article first published online: 22 MAR 2007
- Received on December 8th, 2006. Accepted on December 28th, 2006.
- basal cell carcinoma;
Purpose: To assess the efficacy and safety of topical imiquimod 5% cream in the treatment of eyelid basal cell carcinoma.
Methods: Four patients with eyelid basal cell carcinoma were treated with imiquimod once daily, 5 days per week, for 6 weeks. Tissue biopsy was taken and clinical examination with slit-lamp microscopy was performed at the beginning of the study and after a follow-up of 12 weeks. Photographic follow-up was performed from the baseline visit to 6, 12 and 26 weeks.
Results: In the 12-week follow-up after imiquimod treatment, histopathological tissue sample analysis showed no signs of basal cell carcinoma in any of the patients.
Conclusions: The results indicate that 5% imiquimod cream with topical administration may represent a new therapy option for eyelid basal cell carcinoma.